41036-32-2

Basic information

• Product Name: H-D-ALA-OBZL P-TOSYLATE
• Synonyms: O-benzyl-D-alanine toluene-p-sulphonate;D-Alanine Benzyl Ester p-Toluenesulfonate Salt Also see: A481525;D-Alanine Phenylmethyl Ester 4-Methylbenzenesulfonate;O-Benzyl-D-alanine Toluene-p-sulfonate;D-alanine benzylester 4-methylbenzenesulphonate;L-Alanine benzyl ester 4-methylbenzenesulphonate;D-Alanine benzyl ester p-toluenesulfonate salt ,98%;D-Alanine benzyl est
• CAS NO: 41036-32-2
• Molecular Formula: C₇H₈O₃S*C₁₀H₁₃NO₂
• Molecular Weight: 351.42
• EINECS: 255-185-2
• Product Categories: Amino Acids;Amino Acids and Derivatives;Amino Acids 13C, 2H, 15N;Amino Acid Benzyl Esters;Amino Acids (C-Protected);Biochemistry;Amino ester;Amino Acids & Derivatives;Aromatics;Chiral Reagents;A - H;Amino Acids;Modified Amino Acids
• Mol File: 41036-32-2.mol

Chemical Properties

• Melting Point: 115 °C
• Boiling Point: 256.5 °C at 760 mmHg
• Flash Point: 119.6 °C
• Appearance: Yellowish Oil
• Vapor Pressure: 0.0154mmHg at 25°C
• Refractive Index: 5.0 ° (C=3, MeOH)
• Storage Temp.: −20°C
• Solubility: DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: H-D-ALA-OBZL P-TOSYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: H-D-ALA-OBZL P-TOSYLATE(41036-32-2)
• EPA Substance Registry System: H-D-ALA-OBZL P-TOSYLATE(41036-32-2)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 41036-32-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
H-D-ALA-OBZL P-TOSYLATE is used as a modulator of chemokine receptors for the treatment of inflammatory and immunoregulatory diseases. Its role in modulating these receptors can help in managing and treating various conditions related to inflammation and immune system regulation.
Used in Chemical Industry:
Given its classification as a benzoxazine derivative and its physical state as a yellowish oil, H-D-ALA-OBZL P-TOSYLATE may also find applications in the chemical industry for various purposes, such as a reactant, intermediate, or additive in the synthesis of other compounds or materials. Its specific use would depend on the requirements of the chemical process and the desired outcome.

InChI:InChI=1/C10H13NO2.C7H8O3S/c1-8(11)10(12)13-7-9-5-3-2-4-6-9;1-6-2-4-7(5-3-6)11(8,9)10/h2-6,8H,7,11H2,1H3;2-5H,1H3,(H,8,9,10)/t8-;/m1./s1

Upstream product

• 338-69-2 D-Alanine 
• 104-15-4 toluene-4-sulfonic acid 
• 100-51-6 benzyl alcohol 

Downstream Products

• 736145-05-4 N-(5-phthalimidopentanoyl)-D-alanine benzyl ester 
• 1428244-75-0 C₂₆H₃₉N₅O₇ 
• 1292320-87-6 BocNH-AMCP-(D)Ala-OBn 
• 1257236-54-6 benzyl (2R)-2-morpholin-4-ylpropanoate 
• 1214259-11-6 benzyl N-[2-(benzylamino)benzoyl]-D-alaninate 
• 92261-81-9 PhO-CH2CO-D-Ala(βCl)-D-Ala-OBzl 

Relevant articles and documents

Mortiamides A-D, Cyclic Heptapeptides from a Novel Mortierella sp. Obtained from Frobisher Bay

Four new cyclic heptapeptides, mortiamides A-D (1-4), were obtained from a novel Mortierella sp. isolate obtained from marine sediment collected from the intertidal zone of Frobisher Bay, Nunavut, Canada. The structures of the compounds were elucidated by NMR spectroscopy and tandem mass spectrometry. The absolute configurations of the amino acids were determined using Marfey's method. Localization of l and d amino acids within each compound was ascertained by retention time comparison of the partial hydrosylate products of each compound to synthesized dipeptide standards using LC-HRMS. Compounds 1-4 did not exhibit any significant antimicrobial or cytotoxic activity.

Antiviral phosphoramidates

The invention provides novel nucleoside compounds of formula I wherein R1, R2a, R2b, R3, R4, R5, R6, R8a, R9 and R10 are as defined herein which are useful for the treatment of Hepatitis C Virus (HCV) mediated diseases. The invention further provides methods for treatment or prophylaxis of HCV mediated diseases with compounds of formula I and pharmaceutical compositions comprising these compounds,